Changes of cognitive function in patients with mild to moderate Alzheimer's disease associated with or without white matter lesions after RivastigminE patch thERapy - A multi-center, prospective, open-label clinical trial (CAREER study)

Trial Profile

Changes of cognitive function in patients with mild to moderate Alzheimer's disease associated with or without white matter lesions after RivastigminE patch thERapy - A multi-center, prospective, open-label clinical trial (CAREER study)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms CAREER
  • Most Recent Events

    • 19 Oct 2012 New source identified and integrated (KCT0000551: Clinical Research Information Service (CriS) - Republic of Korea).
    • 15 Aug 2012 Actual initiation date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 15 Aug 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top